Enovis Corporation (ENOV) Stock Price & Analysis

Enovis Corporation (ENOV) closed at USD 21.91 on Wednesday, October 28, 2026, up 1.72% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 21.54; the Oct 28, 2026 session ranged USD 21.46–22.29 on volume of 1,175,547 shares. Market capitalization is $1.26B, with a 52-week range of USD 16.7–33.13 (NYQ). Source: Nexqual, retrieved October 29, 2026 at 10:27 UTC.

Also available as compact Markdown for AI agents: nexqual.com/ENOV.md

Key facts (ENOV)

• Last four reported quarters (through Jul 3, 2026): revenue $2.30B, net income -$1.10B (-48.0% margin), free cash flow $63.7M (SEC filings).
• 1 of 80 tracked superinvestors hold ENOV (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
• Insider open-market purchases, last ~7 months: 7 Form 4 filings, $542K; 0 by opportunistic insiders, 0 by routine insiders.
• Analysts: Buy (mean 1.92 on a 1–5 scale) (13 analysts), mean target USD 36.08 (range 24–47).
• Total return with dividends: 1Y -31.5% vs S&P 500 +13.6%; 5Y -75.3% vs S&P 500 +79.8%.
• Next earnings: 2026-11-05, EPS estimate USD 0.77, revenue estimate $557M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ENOV)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jul 3, 2026) (ENOV)

P/S 0.6x · EV/EBITDA 8.2x · EV/Sales 1.1x · P/FCF 19.8x · P/B 0.9x · FCF yield 5.04% · Earnings yield -87.19% · Net debt $1.27B · EV $2.54B

Superinvestors (SEC 13F-HR, Q2 2026) (ENOV)

1 of 80 tracked investors hold ENOV. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Insider purchases (SEC Form 4, open-market, last ~7 months) (ENOV)

7 purchases, $542K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (ENOV)

Consensus Buy (mean 1.92 on a 1–5 scale), 13 analysts; mean target USD 36.08 (low 24, high 47).

Rating changes, last 120 days:

Total return (dividends reinvested) (ENOV)

ENOV earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

ENOV recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

ENOV suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 26, 2026.

ENOV company outlook (results filed Aug 6, 2026)

• “Enovis reaffirmed financial expectations for 2026.”
• “Revenue is expected to be in a range of $2.31-2.37 billion, which incorporates 4-6% organic revenue growth.”
• “Adjusted EBITDA is expected to be in a range of $425-435 million.”
• “Full-year adjusted earnings per share is expected to be in a range of $3.52 to $3.73.”

Quoted word-for-word from the SEC 8-K results press release.

ENOV analyst estimates and revisions

ENOV options: expected move

Options price a move of about ±18.7% (±$4.10) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±9.7% on average.

30-day implied volatility 74.2% vs 38.6% realized over the last 30 trading days. Put/call ratio (volume) 0.04. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 10:27 UTC)

Technical Analysis (ENOV)

Nexqual's technical model rates ENOV "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 29, 2026 at 10:27 UTC.

Analyst Ratings (ENOV)

Wall Street analysts rate ENOV "Buy" based on 13 analysts, with a mean price target of USD 36.08 (range USD 24–47), per Nexqual as of October 29, 2026 at 10:27 UTC.

Earnings (ENOV)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 10:27 UTC.

Financials & Fundamentals (ENOV)

Source: Nexqual, October 29, 2026 at 10:27 UTC.

Financial Health Score (ENOV)

Nexqual rates Enovis Corporation's overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 10:27 UTC.

Ownership (ENOV)

Source: Nexqual, October 29, 2026 at 10:27 UTC.

Leadership (ENOV)

Enovis Corporation is led by Damien McDonald, CEO & Director, per Nexqual as of October 29, 2026 at 10:27 UTC.

Major Backers & Investors (ENOV)

Notable institutional backers of Enovis Corporation include American Century Companies Inc, Rubric Capital Management LP, Fidelity, according to Nexqual as of October 29, 2026 at 10:27 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 10:27 UTC.

From Enovis Corporation's Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Class I includes devices with the lowest patient risk and are those for which safety and effectiveness can be assured by adherence to the FDA's general controls for medical devices, including compliance with applicable portions of the Quality System Regulation ("QSR") facility registration and product listing, reporting of adverse medical events, and truthful and non-misleading labeling, advertising, and promotional materials.
• The comprehensive range of products we offer enables us to reach a diverse customer base through multiple distribution channels with numerous opportunities to increase our growth across our markets.

Legal & Regulatory Risks (Item 1A, quoted)

• Changes in international trade policy could have a substantial adverse effect on our business, results of operations, financial position and cash flows.
• Our products must be manufactured in accordance with federal and state regulations, and we could be forced to recall our devices or terminate production if we fail to comply with these regulations.
• Our third-party manufacturers may not take the necessary steps to comply with applicable regulations, which could cause delays in the delivery of our products.
• We may be subject to regulatory or enforcement actions if we engage in improper marketing or promotion of our products.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 10:27 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt